BioNTech (BNTX) CEO Sahin Ugur Sells 69,000 Shares

What Happened
Sahin Ugur, CEO of BioNTech SE, reported two sales of ordinary shares totaling 69,000 shares for aggregate proceeds of approximately $6,842,742. On 2026-09-23 he sold 30,000 shares at $99.40 each ($2,982,081) and on 2026-09-24 he sold 39,000 shares at $98.99 each ($3,860,661). These were sales (not purchases), which are commonly routine disposals of stock rather than an expressed bullish signal.

Key Details

• Transaction dates and prices:
  • 2026-09-23: 30,000 shares sold at $99.40 — $2,982,081
  • 2026-09-24: 39,000 shares sold at $98.99 — $3,860,661
• Total sold: 69,000 shares for ~$6.84 million.
• Shares owned after transaction: Not specified in the provided filing. The filing states the ordinary shares are held by Medine GmbH (see footnote).
• Footnote (F1): The shares are held by Medine GmbH; Sahin Ugur is the sole shareholder of Medine GmbH. 106,721 shares referenced are held in trust for an individual where Medine GmbH has voting but not dispositive power; Sahin may be deemed to beneficially own the shares held by Medine.
• Plan and timing: The sales were effected under a Rule 10b5-1 trading plan established on June 3, 2026. The Form 4 was filed on 2026-09-24 for transactions on 2026-09-23 and 2026-09-24 (within the typical two-business-day reporting window).

Context

• Rule 10b5-1 plans are prearranged trading programs that allow insiders to sell shares at preset times/conditions; sales under such plans are often routine and intended to avoid trading on inside information.
• For retail investors, purchases generally carry clearer informational value than routine insider sales; these transactions alone do not indicate the CEO's current view of the company’s prospects.